We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.16 | 0.58% | 27.86 | 27.905 | 27.52 | 27.86 | 60,567,753 | 00:59:06 |
From May 2019 to May 2024
By Colin Kellaher
Pfizer Inc. on Thursday said the U.S. Food and Drug Administration granted fast-track designation to PF-06939926, its investigational gene-therapy candidate in development to treat Duchenne muscular dystrophy.
The New York drugmaker said it currently evaluating PF-06939926 to determine its safety and efficacy.
The FDA's fast-track program is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Duchenne muscular dystrophy, a rare, fatal neuromuscular genetic disease that occurs in roughly one in every 3,500 to 5,000 males, is caused by a change or mutation in the gene that encodes instructions for dystrophin, a protein found in muscle cells.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 01, 2020 07:14 ET (11:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
